StreetInsider.com News Articles

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Tue, 01 Sep 2026 06:12:02 -0400

Lucid Capital Markets analyst Elemer Piros assumes coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Buy rating and a price target of $40.00.

The analyst comments "We estimate NXP100 could achieve net sales of ~$1B in the US (2035) and ~$750M (2036) across EU5 countries. Given NXP100’s approval in China, late-stage efficacy broadly comparable to Fabhalta, and validation of Factor B as a therapeutic target, we apply an 80% PoS, with US regulatory execution representing the primary remaining risk. Our probabilityadjusted, fully taxed NPV is ~$1.4B, supporting our 12-month price target of $40 per share. Factors that could impede shares from

Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy

Tue, 01 Sep 2026 06:12:02 -0400

Lucid Capital Markets analyst Elemer Piros assumes coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Buy rating and a price target of $40.00.

Cantor Fitzgerald Starts Nuvectis Pharma (NVCT) at Overweight

Mon, 24 Aug 2026 06:19:18 -0400

Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ: NVCT) with a Overweight rating.

For an analyst ratings summary and ratings history on Nuvectis Pharma click here. For more ratings news on Nuvectis Pharma click here.

Shares of Nuvectis Pharma closed at $23.56 yesterday.

Nuvectis Pharma (NVCT) files $200M mixed shelf

Fri, 21 Aug 2026 16:41:25 -0400

Nuvectis Pharma (NASDAQ: NVCT) filed $200,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Nuvectis Pharma (NVCT) files $200M mixed shelf

Fri, 21 Aug 2026 16:41:25 -0400

Nuvectis Pharma (NASDAQ: NVCT) filed $200,000,000 mixed shelf of:

Common Stock

Preferred Stock

Warrants

Debt Securities

Units

Form S-3 Nuvectis Pharma, Inc.

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961927.html

Form S-3 Nuvectis Pharma, Inc.

Fri, 21 Aug 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260821/26961927.html

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961822.html

Form 8-K Nuvectis Pharma, Inc. For: Jul 20

Fri, 21 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260821/26961822.html

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Thu, 06 Aug 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26881717.html

Form SCHEDULE 13G Nuvectis Pharma, Inc. Filed by: Soleus Private Equity Fund III, L.P.

Thu, 06 Aug 2026 11:29:00 -0400

si-local-file:///var/storage/secattach/20260806/26881717.html

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Wed, 05 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260805/26876077.html

Form 4 Nuvectis Pharma, Inc. For: Aug 03 Filed by: Carson Michael J.

Wed, 05 Aug 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260805/26876077.html

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Tue, 04 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26862954.html

Form 10-Q Nuvectis Pharma, Inc. For: Jun 30

Tue, 04 Aug 2026 09:02:00 -0400

si-local-file:///var/storage/secattach/20260804/26862954.html

Form 8-K Nuvectis Pharma, Inc. For: Aug 04

Tue, 04 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260804/26862263.html

Form 8-K Nuvectis Pharma, Inc. For: Aug 04

Tue, 04 Aug 2026 08:25:00 -0400

si-local-file:///var/storage/secattach/20260804/26862263.html

Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights